KRAS and colorectal carcinoma: In addition, EGF and EGFR levels dramatically decreased after being treated with the combination compared to single-agent heteronemin in HT-29 cells (KRAS WT CRC) and HCT-116 cells (KRAS MT CRC), respectively (Figure 7A,D).